Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Therapeutic Equivalence Evaluations Would Be Required For 505(b)(2) Drugs Under Senate User Fee Bill

Jun 02 2022

• By Brenda Sandburg

Equivalence — FDA would have to provide therapeutic equivalence codes for certain generics under Senate user fee bill • Source: Shutterstock

Related Content

Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances

May 30 2022

Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances

May 26 2022

House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

May 19 2022

Accelerated Approval, Clinical Trial Diversity Provisions Left Out Of Senate User Fee Bill

May 18 2022

US FDA Accelerated Approval Council Required Under Senate User Fee Bill

May 31 2022

Inactive Ingredient Disclosure Expansion In House User Fee Bill Poised For Changes

May 11 2022

Additional Topics

United States Legislation User Fees Generic Drugs Policy FDA BioPharmaceutical

More from Policy & Regulation

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window